Lower gastrointestinal bleeding initial resuscitation

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Muhammad Saad, M.D.[2] Aditya Ganti M.B.B.S. [3]

Management

Initial assessment and resuscitation

• Manage acute LGIB using an airway, breathing, circulation (ABC) approach with immediate assessment of hemodynamic status and bleeding severity. Establish two large-bore peripheral intravenous lines for crystalloid and blood-product administration.
• Obtain baseline laboratory studies at presentation, including complete blood count, electrolytes and renal function, coagulation studies, and blood typing with crossmatch.
• In patients with hemodynamic instability, administer intravenous crystalloid and use goal-directed reassessment to restore adequate perfusion and improve blood pressure and heart rate before definitive diagnostic or therapeutic intervention.
• Reassess volume status frequently, particularly in older patients and those with cardiopulmonary comorbidity, to avoid excessive fluid administration.
• The shock index (heart rate/systolic blood pressure) can assist initial triage; a value >1 is associated with hemodynamic instability and should prompt urgent evaluation and consideration of CT angiography when appropriate.

Red blood cell transfusion

• In hemodynamically stable patients, use a restrictive red blood cell transfusion strategy with a hemoglobin threshold of approximately 7 g/dL. LGIB-specific randomized trial data are limited, and this recommendation is substantially extrapolated from evidence in upper gastrointestinal bleeding.
• A hemoglobin threshold of approximately 8 g/dL may be considered in patients with preexisting cardiovascular disease or acute coronary syndrome, although LGIB-specific evidence is limited.
• Because hemoglobin may lag behind acute blood loss and may fall further after fluid resuscitation, patients with ongoing severe hemorrhage, hemodynamic instability, or hypotension should not be required to reach a hemoglobin concentration of 7 g/dL before transfusion is initiated.
• Restrictive transfusion thresholds should not be applied rigidly to patients with hemorrhagic shock or massive/ongoing active bleeding; transfusion should be individualized according to the severity of hemorrhage and institutional massive hemorrhage protocols.

Platelets and correction of coagulopathy

• Do not routinely transfuse platelets solely because a patient is receiving antiplatelet therapy. In clinically significant bleeding, platelet transfusion may be considered to maintain a platelet count above 30 × 10⁹/L; a threshold above 50 × 10⁹/L may be considered when an invasive or endoscopic procedure is required.
• Endoscopic intervention can generally be performed without complete normalization of the INR. In severe bleeding with hemodynamic instability and substantially supratherapeutic anticoagulation, reversal should be considered according to the anticoagulant involved.

Management of antithrombotic therapy

• Warfarin: Hold warfarin during significant acute bleeding. When reversal is required, 4-factor prothrombin complex concentrate (PCC) is preferred over fresh frozen plasma (FFP) because of its more rapid and predictable correction of anticoagulation.
• Direct oral anticoagulants (DOACs): For significant bleeding, initially withhold the DOAC and provide supportive and source-directed management. Routine reversal is not recommended for most patients; however, selective reversal may be considered in life-threatening bleeding with hemodynamic instability, taking into account the specific DOAC, timing of the last dose, renal function, severity of bleeding, and thrombotic risk.
• For dabigatran-associated life-threatening bleeding, idarucizumab may be considered when specific reversal is required. For factor Xa inhibitor-associated bleeding, targeted reversal strategies require consideration of current drug availability and local/regulatory guidance.
• Andexanet alfa (Andexxa) was withdrawn from the U.S. market effective 22 December 2025. The FDA determined that its risks, including thromboembolic events, outweighed its benefits.
• Aspirin for secondary cardiovascular prevention: Do not routinely interrupt aspirin. If it must be temporarily interrupted because of severe bleeding, resume it on the day that endoscopic hemostasis is confirmed.
• Aspirin for primary prevention: Hold aspirin during significant bleeding and generally discontinue it when the indication is solely primary prevention.
• Dual antiplatelet therapy: Continue aspirin and temporarily hold the P2Y12 inhibitor when clinically necessary. In patients with a recent coronary stent, particularly within the first year, decisions regarding interruption should be individualized with cardiology because of the risk of stent thrombosis.

Consideration of an upper gastrointestinal source

• Severe hematochezia accompanied by hemodynamic instability can result from a brisk upper gastrointestinal source. When clinical suspicion for upper GI bleeding is high, EGD should be considered before colonoscopic evaluation.
• Routine nasogastric aspiration or lavage is not recommended for excluding an upper GI source because of poor diagnostic sensitivity; reported sensitivity was only approximately 28%.
• An elevated blood urea nitrogen-to-creatinine ratio increases suspicion for an upper GI source; a BUN:creatinine ratio >30 has been associated with a likelihood ratio of approximately 7.5 for upper GI bleeding. Conversely, blood clots in the stool argue against an upper GI source (likelihood ratio approximately 0.05). These findings should supplement rather than replace clinical assessment.

Key principles

• Stabilize airway, breathing, and circulation before definitive diagnostic or therapeutic intervention.
• Obtain baseline laboratory studies and prepare blood products early in patients with significant or ongoing hemorrhage.
• Use goal-directed crystalloid resuscitation in hemodynamically unstable patients and reassess frequently.
• In stable patients, use a restrictive hemoglobin threshold of approximately 7 g/dL for RBC transfusion; consider approximately 8 g/dL in patients with cardiovascular disease or acute coronary syndrome.
• Do not wait for a hemoglobin concentration of 7 g/dL in patients with severe ongoing hemorrhage or hemodynamic instability.
• Manage anticoagulant and antiplatelet therapy according to the specific agent, severity of bleeding, and thrombotic risk rather than applying a uniform reversal strategy.
• Consider an upper GI source in patients with severe hematochezia and hemodynamic instability.
• Definitive source localization and hemostasis with CT angiography, colonoscopy, angiography, or surgery are addressed in dedicated diagnostic and therapeutic microchapters.